8-K: Clover Health Reports Q3 2025 Results, Cuts Profit Outlook

Clover Health Investments, Corp. announced its third quarter 2025 financial results, reporting significant membership and revenue growth but revising down its full-year 2025 profitability guidance.

Summary

• Third quarter 2025 Medicare Advantage membership reached 109,226, marking a 35% year-over-year increase.
• Total revenues for Q3 2025 were $497 million, up 50% year-over-year.
• The company reported a GAAP Net loss of $24 million for Q3 2025.
• Adjusted EBITDA for Q3 2025 was $2 million, with Adjusted Net income also at $2 million.
• Year-to-date Q3 2025 GAAP Net loss was $36 million, while Adjusted EBITDA was $45 million and Adjusted Net Income was $44 million.
• Revised full-year 2025 guidance now projects Average Medicare Advantage membership between 106,000 and 108,000, representing 33% growth year-over-year at the midpoint.
• Full-year 2025 Insurance revenue guidance increased to between $1.850 billion and $1.880 billion, indicating 39% growth year-over-year at the midpoint.
• Adjusted SG&A for full-year 2025 is expected to be between $325 million and $335 million, or 17% 18% of Total revenues.
• Revised full-year 2025 Adjusted EBITDA and Adjusted Net income profitability guidance is now between $15 million and $30 million.
• The Insurance Benefits Expense Ratio (BER) for full-year 2025 is expected to be between 90% and 91%.

Sentiment

Score: 5

Explanation: While Clover Health demonstrates strong top-line growth in membership and revenue, the substantial downward revision of its full-year 2025 Adjusted EBITDA and Net Income guidance, coupled with a significant year-over-year decline in Q3 profitability metrics, indicates challenges in translating growth into consistent earnings. The increase in Insurance BER suggests rising medical costs, particularly from new members. However, the company's positive year-to-date Adjusted EBITDA, strong retention, and a positive directional outlook for 2026 (driven by Star ratings, CMS rates, and Part D subsidies) provide some optimism for future improvement.

Positives

• Achieved strong membership growth of 35% year-over-year in Q3 2025, reaching 109,226 Medicare Advantage members.
• Reported significant revenue growth of 50% year-over-year in Q3 2025, with total revenues of $497 million.
• Maintained positive Adjusted EBITDA ($45 million) and Adjusted Net Income ($44 million) on a year-to-date basis for Q3 2025.
• Increased full-year 2025 guidance for Average Medicare Advantage membership and Insurance revenue.
• Improved the projected Adjusted SG&A as a percentage of Total revenues for full-year 2025 to 17% 18% from previous guidance of 18% 19%.
• Anticipates increasing Adjusted EBITDA profitability for full-year 2026, driven by strong returning member economics, a 4.0 Star payment year, favorable CMS rate updates, and increased Part D direct subsidy.
• High coverage of Clover Assistant, including within new cohorts, is expected to result in improved total cost of care.
• Reported strong retention and above-market growth, positioning the company for improved positive FY26 financial results.

Negatives

• Reported a GAAP Net loss of $24 million in Q3 2025 and $36 million year-to-date, indicating continued unprofitability under GAAP measures.
• Adjusted EBITDA for Q3 2025 was $2.1 million, a significant decrease from $19.3 million in Q3 2024.
• Adjusted Net income for Q3 2025 was $1.7 million, a substantial drop from $18.9 million in Q3 2024.
• Revised full-year 2025 guidance for Adjusted EBITDA and Adjusted Net income profitability was significantly lowered from the previous range of $50 million $70 million to $15 million $30 million.
• The Insurance Benefits Expense Ratio (BER) increased to 93.5% in Q3 2025 from 82.8% in Q3 2024, indicating higher medical costs relative to premiums.
• Experienced margin pressures during Q3 due to a higher-than-expected mix of new members with elevated inpatient and outpatient utilization.
• Total cash, cash equivalents, and investments decreased by 25.5% from $531.4 million at September 30, 2024, to $395.9 million at September 30, 2025.

Risks

• Expectations regarding results of operations, financial condition, and cash flows may not be met.
• The development and management of the business may face unforeseen challenges.
• Current, pending, or future legislation, regulations, or policies related to healthcare, Medicare, and medical loss ratios could negatively impact revenue, profit margins, and cash flows.
• The ability to successfully enter new service markets and manage operations effectively is not guaranteed.
• Challenges may arise in effectively managing the beneficiary base and provider network.
• The ability to maintain and increase adoption and use of Clover Assistant, including its expansion under Counterpart Assistant, may not be successful.
• The anticipated benefits of utilizing the Clover Assistant platform to manage medical expenses may not be fully realized.
• The company may not be able to maintain or improve its Star Ratings or otherwise continue to improve the financial performance of its business.
• Developing new features and functionality that meet market needs and achieve market acceptance could be difficult.
• The ability to retain and hire necessary employees and staff operations appropriately is a continuous challenge.
• The timing and amount of certain investments in growth may not yield expected returns.
• The outcome of any known and unknown litigation and regulatory proceedings could be adverse.
• Maintaining, protecting, and enhancing intellectual property is crucial and subject to risks.
• General economic conditions and uncertainty, persistent high inflation, fluctuating interest rates, and geopolitical uncertainty and instability could negatively affect the business.

Future Outlook

The company expects to provide formal full-year 2026 guidance next year, but directionally anticipates achieving full-year GAAP Net Income in 2026. This is expected to be driven by a favorable financial impact from the upcoming 4.0 Star payment year, continued strong cohort management and focus on returning member retention, a favorable 2026 CMS final rate update, and an increased Part D direct subsidy. The company also plans to continue cost efficiency initiatives to optimize variable, fixed, and growth SG&A, aiming for above-market growth and increasing profitability in 2026 and beyond.

Management Comments

• CEO Andrew Toy stated: "Our model of care continues to perform well as we bring our technology-powered care to more Medicare Advantage seniors. With Clover Assistant powering profitable returning member cohort performance, we remain confident in 2026 to continue to grow above-market and achieve strong retention, as well as lead with affordability, choice, and great benefits. We believe that the combination of more members, more Clover Assistant engaged physicians, and earlier disease management reinforces the strength of our model and our ability to drive better outcomes for our members."
• CFO Peter Kuipers commented: "Our results this year reflect our continued ability to drive strong revenue and membership growth while sustaining positive Adjusted EBITDA profitability year-to-date. The margin pressures that we experienced during the third quarter reflect a higher-than-expected mix of new members, relative to our returning base, with elevated inpatient and outpatient utilization. Despite these pressures, our underlying incurred medical cost trend, excluding pharmacy, was 4%, while growing membership 35% year-over-year. Given our strong member retention and profitable returning member cohorts, we anticipate profitability improvement in the years ahead as new members mature into returning cohorts. Together with our 2026 tailwinds, including a 4 Star payment year, favorable rate increase, our ability to increase PCP CA adoption and enhance our platforms capabilities, and our ability to optimize SG&A, we believe that we are well positioned to achieve above-market growth and increasing profitability in 2026 and beyond."

Industry Context

Clover Health's performance reflects the dynamic nature of the Medicare Advantage market, characterized by intense competition, regulatory influences (like CMS Star Ratings and rate updates), and the challenge of balancing growth with profitability. The company's strategy of leveraging its Clover Assistant technology to improve care outcomes and manage costs aligns with broader industry trends towards value-based care and digital health solutions. The reported margin pressures from a high mix of new members with elevated utilization are a common challenge for MA plans experiencing rapid growth, as new members often have higher initial healthcare costs before care management programs can take full effect.

Stakeholder Impact

• Shareholders: Face increased uncertainty due to the significant reduction in full-year profitability guidance, despite strong revenue and membership growth. Future value creation depends on the company's ability to execute on its 2026 profitability drivers and manage medical costs effectively.
• Members: Continue to benefit from technology-powered care through Clover Assistant, with a focus on affordability, choice, and comprehensive benefits within Medicare Advantage plans.
• Healthcare Providers: Will see continued emphasis on engagement with Clover Assistant to support clinical decision-making and improve health outcomes, potentially leading to better patient management.
• Employees: The company's focus on growth and cost efficiency initiatives suggests a dynamic work environment with an emphasis on performance and operational optimization.

Next Steps

• Management will host a conference call on November 4, 2025, at 5:00 p.m. ET to discuss operating results and business highlights.
• Clover Health will attend the 2025 UBS Global Healthcare Conference on November 11, 2025.
• The company intends to provide formal full-year 2026 guidance next year.
• Continue to drive strong, sustainable growth, similar to 2025.
• Focus on strong returning member cohort economics and high expected retention.
• Increase PCP Clover Assistant adoption and enhance the platform's capabilities.
• Implement cost efficiency initiatives to optimize variable, fixed, and growth SG&A.

Key Dates

Recommendation

While Clover Health demonstrates strong top-line growth in membership and revenue, the substantial downward revision of its full-year 2025 Adjusted EBITDA and Net Income guidance, coupled with a significant year-over-year decline in Q3 profitability metrics, raises concerns about its ability to convert growth into sustainable earnings. The increase in Insurance BER indicates rising medical costs, particularly from new members. However, the company's positive year-to-date Adjusted EBITDA, strong retention, and a positive directional outlook for 2026 (driven by Star ratings, CMS rates, and Part D subsidies) suggest potential for future improvement. Given the mixed signals – strong growth but weaker-than-expected profitability in the short term, offset by a more optimistic long-term view – a 'hold' recommendation is appropriate for investors to observe if the company can execute on its 2026 profitability drivers and improve its BER.

Keywords

Clover Health, CLOV, Medicare Advantage, Q3 2025, financial results, earnings, Adjusted EBITDA, revenue growth, membership growth, healthcare technology, Clover Assistant, insurance, health insurance, medical claims, SG&A, guidance, 2026 outlook